Rilmenidin

Rilmenidin
(IUPAC) ime
	N-(diciklopropilmetil)-4,5-dihidro-1,3-oksazol-2-amin
Klinički podaci
AHFS/Drugs.com	Internacionalno ime leka
Identifikatori
CAS broj	54187-04-1
ATC kod	C02AC06
PubChem	68712
ChemSpider	61963
UNII	P67IM25ID8
ChEMBL	CHEMBL289480
Hemijski podaci
Formula	C10H16N2O
Mol. masa	180,247 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12) ; Key: CQXADFVORZEARL-UHFFFAOYSA-N
Farmakokinetički podaci
Vezivanje za proteine plazme	7%
Metabolizam	Minimalan
Poluvreme eliminacije	8 sata
Izlučivanje	Renalno, nepromenjen
Farmakoinformacioni podaci
Trudnoća	?
Pravni status
Način primene	Oralno

Rilmenidin je lek koji se koristi za treatiranje hipertenzije.^[5] On je u prodaji pod imenima Hyperium i Tenaxum.

Tableta uredi

Svaka tableta sadrži 1,544 mg rilmenidin dihidrogen fosfata, količinu ekvuivalentnu sa 1,000 mg slobodne baze rilmenidina.

Način dejstva uredi

Rilmenidin je oksazolinsko jedinjenje sa antihipertenzivnim svojstvima. On deluje na medularne i periferno vazomotorne strukture. Rilmenidin ima veću selektivnost za imidazolinske receptore nego za cerebralne alfa2-adrenergičke receptore, po čemu se razlikuje od referentnih alfa-2 agonista.

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Remková A, Kratochvíl'ová H (August 2002). „Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension”. J Hum Hypertens 16 (8): 549–55. DOI:10.1038/sj.jhh.1001427. PMID 12149660.

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[pmid12149660-5] Remková A, Kratochvíl'ová H (August 2002). „Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension”. J Hum Hypertens 16 (8): 549–55. DOI:10.1038/sj.jhh.1001427. PMID 12149660.

[5]

[1]

[2]

[3]

[4]